{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T20:58:02Z","timestamp":1696625882542},"reference-count":24,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T00:00:00Z","timestamp":1377820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Italian Association for Leukemias, Lymphomas, and Myeloma (AIL, Bologna, Italy)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>There is no international consensus on front\u2010line optimal chemotherapy regimen for advanced stage follicular lymphoma (FL) patients, or a clear definition of cure for this disease. Aim of this study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab in a subset of poor prognosis FL patients with particular focus on the long\u2010term disease\u2010free survival. A retrospective study was conducted on 142 intermediate\/high\u2010risk FL patients treated in first\u2010line with fludarabine, mitoxantrone, and rituximab regimen. Responses, safety, and survival were evaluated. The prognostic value of positron emission tomography (PET) was also investigated in a 56\u2010patients subset. Overall response rate was 95.5% including 88% of complete responses. With a median follow\u2010up of 48 months, 18% of patients had disease relapse, yielding an estimated 12\u2010year disease\u2010free survival (DFS) of 72%. All cases showed the lymphoma recurrence within 40 months: after this timing the DFS curve presented a plateau. Overall survival was 73% at 12 years. Post\u2010treatment PET positivity remains a highly significant predictor of disease progression. The observed high rate of complete responses following the use of fludarabine, mitoxantrone\u2010based regimen in combination with rituximab seems to be the first step to improve DFS. Our study could be the starting point to consider DFS as a potential alternative endpoint of future clinical trials on FL patients. Am. J. Heamtol. 88:E273\u2013E276, 2013. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23540","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T14:34:42Z","timestamp":1373466882000},"source":"Crossref","is-referenced-by-count":8,"title":["Fludarabine\u2010mitoxantrone\u2010rituximab regimen in untreated intermediate\/high\u2010risk follicular non\u2010Hodgkin's lymphoma: Experience on 142 patients"],"prefix":"10.1002","volume":"88","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-041863"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70039-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.170"},{"key":"e_1_2_7_10_1","volume-title":"Presented at the 51st American society of Hematology Annual Meeting and exposition","author":"Rummel MJ","year":"2009"},{"key":"e_1_2_7_11_1","first-page":"3","article-title":"Bendamustine plus rituximab (B\u2010R) versus CHOP plus rituximab (CHOP\u2010R) as first\u2010line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study","volume":"30","author":"Rummel MJ","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_13_1","first-page":"8006","article-title":"R\u2010CVP versus R\u2010CHOP versus R\u2010FM as first\u2010line therapy for advanced\u2010stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL)","volume":"30","author":"Federico M","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22649"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.04.012"},{"key":"e_1_2_7_21_1","first-page":"1088","article-title":"Prolonged clinical and molecular remission in patients with low\u2010grade or follicular non\u2010Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9\u2010year follow\u2010up","volume":"23","author":"Czuczman MS","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123564"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl039"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.5950"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0736"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23540","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.23540","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T14:55:30Z","timestamp":1692543330000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/ajh.23540"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23540","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,30]]}}}